Top Qs
Timeline
Chat
Perspective

ADB-CHMINACA

Chemical compound From Wikipedia, the free encyclopedia

ADB-CHMINACA
Remove ads

ADB-CHMINACA (also known as ADMB-CHMINACA[3] and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[4][5] It was identified in cannabinoid blends in Japan in early 2015.[6]

Quick Facts Legal status, Identifiers ...
Remove ads

Side effects

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[7][8][9][10][11][12][13][14]

In the United States, ADB-CHMINACA is a Schedule I controlled substance.[15] Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.[16]

Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.[17]

ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[18]

ADB-CHMINACA is illegal in Switzerland as of December 2015.[19]

Metabolism

Ten ADB-CHMINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Most transformations occurred at the cyclohexylmethyl tail of the compound.[20]

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads